ProChon Biotech Ltd. Nearing Midpoint of Patient Enrollment for BioCart Clinical Study

WOBURN, Mass.--(BUSINESS WIRE)--ProChon Biotech, Ltd., an innovator of tissue regenerative technologies that are being developed to relieve pain and restore the mobility and quality-of-life for sufferers of articular cartilage injuries, today announced that patient enrollment in the Company’s Phase II study of the BioCart™ Autologous Cartilage System is nearing the halfway point and is expected to be completed within the next three months. The randomized, double-arm, open-label, multicenter Phase II study compares the safety and efficacy of the BioCart™ System to microfracture for the treatment of symptomatic cartilage defects.